nodes	percent_of_prediction	percent_of_DWPC	metapath
Lisdexamfetamine—attention deficit hyperactivity disorder—Clonidine—glaucoma	0.644	1	CpDpCtD
Lisdexamfetamine—ADRA1B—Clonidine—glaucoma	0.0761	0.523	CbGbCtD
Lisdexamfetamine—SLC6A2—Clonidine—glaucoma	0.0695	0.477	CbGbCtD
Lisdexamfetamine—SLC18A2—Dopaminergic Neurogenesis—LMX1B—glaucoma	0.00389	0.0905	CbGpPWpGaD
Lisdexamfetamine—Lisinopril—ACE2—glaucoma	0.00277	0.701	CrCbGaD
Lisdexamfetamine—SLC18A2—Na+/Cl- dependent neurotransmitter transporters—SLC6A13—glaucoma	0.00252	0.0588	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Dopaminergic Neurogenesis—LMX1B—glaucoma	0.00232	0.0539	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Na+/Cl- dependent neurotransmitter transporters—SLC6A1—glaucoma	0.00185	0.043	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Amine compound SLC transporters—SLC6A13—glaucoma	0.00175	0.0408	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Na+/Cl- dependent neurotransmitter transporters—SLC6A13—glaucoma	0.0017	0.0396	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Na+/Cl- dependent neurotransmitter transporters—SLC6A13—glaucoma	0.00151	0.035	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Neurotransmitter Release Cycle—SLC6A13—glaucoma	0.00134	0.0312	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Amine compound SLC transporters—SLC6A1—glaucoma	0.00128	0.0299	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Na+/Cl- dependent neurotransmitter transporters—SLC6A1—glaucoma	0.00124	0.0289	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Amine compound SLC transporters—SLC6A13—glaucoma	0.00118	0.0274	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Na+/Cl- dependent neurotransmitter transporters—SLC6A1—glaucoma	0.0011	0.0256	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Amine compound SLC transporters—SLC6A13—glaucoma	0.00104	0.0243	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Neurotransmitter Release Cycle—SLC6A1—glaucoma	0.00098	0.0228	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Amine compound SLC transporters—SLC6A1—glaucoma	0.000863	0.0201	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Monoamine Transport—SLC6A1—glaucoma	0.000819	0.0191	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Amine compound SLC transporters—SLC6A1—glaucoma	0.000764	0.0178	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Monoamine Transport—SLC6A1—glaucoma	0.000726	0.0169	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC6A13—glaucoma	0.000685	0.016	CbGpPWpGaD
Lisdexamfetamine—Lacosamide—CA1—glaucoma	0.000673	0.17	CrCbGaD
Lisdexamfetamine—Lacosamide—CA2—glaucoma	0.00051	0.129	CrCbGaD
Lisdexamfetamine—SLC18A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC6A1—glaucoma	0.000502	0.0117	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—SLC-mediated transmembrane transport—SLC4A4—glaucoma	0.000467	0.0109	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC6A13—glaucoma	0.000461	0.0107	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—AMPK Signaling—RPTOR—glaucoma	0.000451	0.0105	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC6A13—glaucoma	0.000408	0.00951	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmission across Chemical Synapses—SLC6A13—glaucoma	0.000384	0.00894	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmembrane transport of small molecules—PEX19—glaucoma	0.000351	0.00817	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC6A1—glaucoma	0.000337	0.00786	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—NRF2 pathway—SLC6A13—glaucoma	0.000332	0.00774	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Alpha-synuclein signaling—BAD—glaucoma	0.000316	0.00736	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—SLC-mediated transmembrane transport—SLC4A4—glaucoma	0.000314	0.00731	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—SLC-mediated transmembrane transport—SLC6A13—glaucoma	0.000311	0.00725	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC6A1—glaucoma	0.000299	0.00696	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—NRF2 pathway—SLC6A13—glaucoma	0.000294	0.00686	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Neuronal System—SLC6A13—glaucoma	0.000294	0.00685	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—G alpha (q) signalling events—OPN4—glaucoma	0.000288	0.00672	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmission across Chemical Synapses—SLC6A1—glaucoma	0.000281	0.00654	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—SLC-mediated transmembrane transport—SLC4A4—glaucoma	0.000278	0.00648	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—NRF2 pathway—TXN—glaucoma	0.000273	0.00636	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—G alpha (q) signalling events—PTGFR—glaucoma	0.00026	0.00605	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—OPN4—glaucoma	0.000258	0.00601	CbGpPWpGaD
Lisdexamfetamine—Dry mouth—Travoprost—glaucoma	0.000256	0.00157	CcSEcCtD
Lisdexamfetamine—Acute coronary syndrome—Betaxolol—glaucoma	0.000256	0.00157	CcSEcCtD
Lisdexamfetamine—Myocardial infarction—Betaxolol—glaucoma	0.000254	0.00156	CcSEcCtD
Lisdexamfetamine—Dizziness—Latanoprost—glaucoma	0.000254	0.00156	CcSEcCtD
Lisdexamfetamine—Dry mouth—Brinzolamide—glaucoma	0.000253	0.00155	CcSEcCtD
Lisdexamfetamine—Vomiting—Methazolamide—glaucoma	0.000252	0.00155	CcSEcCtD
Lisdexamfetamine—Anaphylactic shock—Dorzolamide—glaucoma	0.000252	0.00154	CcSEcCtD
Lisdexamfetamine—Hypertension—Pilocarpine—glaucoma	0.000252	0.00154	CcSEcCtD
Lisdexamfetamine—Abdominal pain upper—Timolol—glaucoma	0.000251	0.00154	CcSEcCtD
Lisdexamfetamine—Rash—Methazolamide—glaucoma	0.00025	0.00153	CcSEcCtD
Lisdexamfetamine—Dermatitis—Methazolamide—glaucoma	0.00025	0.00153	CcSEcCtD
Lisdexamfetamine—Eye disorder—Clonidine—glaucoma	0.00025	0.00153	CcSEcCtD
Lisdexamfetamine—Nausea—Carbachol—glaucoma	0.00025	0.00153	CcSEcCtD
Lisdexamfetamine—Headache—Methazolamide—glaucoma	0.000249	0.00152	CcSEcCtD
Lisdexamfetamine—Cardiac disorder—Clonidine—glaucoma	0.000248	0.00152	CcSEcCtD
Lisdexamfetamine—Anxiety—Pilocarpine—glaucoma	0.000247	0.00152	CcSEcCtD
Lisdexamfetamine—Nausea—Levobunolol—glaucoma	0.000246	0.00151	CcSEcCtD
Lisdexamfetamine—Nervous system disorder—Travoprost—glaucoma	0.000246	0.00151	CcSEcCtD
Lisdexamfetamine—Tachycardia—Travoprost—glaucoma	0.000245	0.0015	CcSEcCtD
Lisdexamfetamine—Somnolence—Acetazolamide—glaucoma	0.000244	0.0015	CcSEcCtD
Lisdexamfetamine—ADRA1B—GPCRs, Class A Rhodopsin-like—MAS1—glaucoma	0.000244	0.00568	CbGpPWpGaD
Lisdexamfetamine—Skin disorder—Travoprost—glaucoma	0.000244	0.00149	CcSEcCtD
Lisdexamfetamine—Hyperhidrosis—Dorzolamide—glaucoma	0.000244	0.00149	CcSEcCtD
Lisdexamfetamine—SLC6A2—NRF2 pathway—SLC6A1—glaucoma	0.000243	0.00566	CbGpPWpGaD
Lisdexamfetamine—Nervous system disorder—Brinzolamide—glaucoma	0.000243	0.00149	CcSEcCtD
Lisdexamfetamine—Rash—Latanoprost—glaucoma	0.000242	0.00148	CcSEcCtD
Lisdexamfetamine—Dermatitis—Latanoprost—glaucoma	0.000242	0.00148	CcSEcCtD
Lisdexamfetamine—Dyspepsia—Acetazolamide—glaucoma	0.000242	0.00148	CcSEcCtD
Lisdexamfetamine—SLC6A3—NRF2 pathway—TXN—glaucoma	0.000242	0.00563	CbGpPWpGaD
Lisdexamfetamine—Tachycardia—Brinzolamide—glaucoma	0.000242	0.00148	CcSEcCtD
Lisdexamfetamine—Mediastinal disorder—Clonidine—glaucoma	0.000241	0.00148	CcSEcCtD
Lisdexamfetamine—Headache—Latanoprost—glaucoma	0.000241	0.00147	CcSEcCtD
Lisdexamfetamine—Skin disorder—Brinzolamide—glaucoma	0.000241	0.00147	CcSEcCtD
Lisdexamfetamine—Anorexia—Dorzolamide—glaucoma	0.00024	0.00147	CcSEcCtD
Lisdexamfetamine—Decreased appetite—Acetazolamide—glaucoma	0.000239	0.00146	CcSEcCtD
Lisdexamfetamine—Insomnia—Brimonidine—glaucoma	0.000239	0.00146	CcSEcCtD
Lisdexamfetamine—Gastrointestinal disorder—Acetazolamide—glaucoma	0.000237	0.00145	CcSEcCtD
Lisdexamfetamine—SLC18A2—Transmembrane transport of small molecules—SLC4A4—glaucoma	0.000237	0.00552	CbGpPWpGaD
Lisdexamfetamine—Fatigue—Acetazolamide—glaucoma	0.000237	0.00145	CcSEcCtD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—PEX19—glaucoma	0.000236	0.0055	CbGpPWpGaD
Lisdexamfetamine—Nausea—Methazolamide—glaucoma	0.000236	0.00144	CcSEcCtD
Lisdexamfetamine—Dyspnoea—Brimonidine—glaucoma	0.000235	0.00144	CcSEcCtD
Lisdexamfetamine—Somnolence—Brimonidine—glaucoma	0.000234	0.00144	CcSEcCtD
Lisdexamfetamine—Mental disorder—Clonidine—glaucoma	0.000234	0.00144	CcSEcCtD
Lisdexamfetamine—Tachycardia—Pilocarpine—glaucoma	0.000232	0.00142	CcSEcCtD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—PTGFR—glaucoma	0.000232	0.00541	CbGpPWpGaD
Lisdexamfetamine—Dyspepsia—Brimonidine—glaucoma	0.000232	0.00142	CcSEcCtD
Lisdexamfetamine—Hallucination—Betaxolol—glaucoma	0.000232	0.00142	CcSEcCtD
Lisdexamfetamine—Hyperhidrosis—Pilocarpine—glaucoma	0.00023	0.00141	CcSEcCtD
Lisdexamfetamine—SLC6A3—Transmission across Chemical Synapses—SLC6A13—glaucoma	0.000229	0.00533	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—SLC-mediated transmembrane transport—SLC6A1—glaucoma	0.000228	0.00531	CbGpPWpGaD
Lisdexamfetamine—Insomnia—Dorzolamide—glaucoma	0.000228	0.0014	CcSEcCtD
Lisdexamfetamine—Gastrointestinal disorder—Brimonidine—glaucoma	0.000228	0.00139	CcSEcCtD
Lisdexamfetamine—Fatigue—Brimonidine—glaucoma	0.000227	0.00139	CcSEcCtD
Lisdexamfetamine—Anorexia—Pilocarpine—glaucoma	0.000227	0.00139	CcSEcCtD
Lisdexamfetamine—Hypersensitivity—Apraclonidine—glaucoma	0.000226	0.00139	CcSEcCtD
Lisdexamfetamine—Nervousness—Clonidine—glaucoma	0.000226	0.00139	CcSEcCtD
Lisdexamfetamine—Dyspnoea—Dorzolamide—glaucoma	0.000225	0.00138	CcSEcCtD
Lisdexamfetamine—Visual impairment—Betaxolol—glaucoma	0.000224	0.00138	CcSEcCtD
Lisdexamfetamine—Insomnia—Brinzolamide—glaucoma	0.000224	0.00137	CcSEcCtD
Lisdexamfetamine—Somnolence—Dorzolamide—glaucoma	0.000224	0.00137	CcSEcCtD
Lisdexamfetamine—Dyspnoea—Travoprost—glaucoma	0.000224	0.00137	CcSEcCtD
Lisdexamfetamine—ADRA1B—GPCRs, Class A Rhodopsin-like—OPN4—glaucoma	0.000223	0.00519	CbGpPWpGaD
Lisdexamfetamine—Dyspepsia—Dorzolamide—glaucoma	0.000222	0.00136	CcSEcCtD
Lisdexamfetamine—Dyspnoea—Brinzolamide—glaucoma	0.000221	0.00135	CcSEcCtD
Lisdexamfetamine—Dyspepsia—Travoprost—glaucoma	0.000221	0.00135	CcSEcCtD
Lisdexamfetamine—Asthenia—Apraclonidine—glaucoma	0.00022	0.00135	CcSEcCtD
Lisdexamfetamine—Somnolence—Brinzolamide—glaucoma	0.00022	0.00135	CcSEcCtD
Lisdexamfetamine—Vision blurred—Clonidine—glaucoma	0.00022	0.00134	CcSEcCtD
Lisdexamfetamine—Decreased appetite—Dorzolamide—glaucoma	0.000219	0.00134	CcSEcCtD
Lisdexamfetamine—Erectile dysfunction—Timolol—glaucoma	0.000219	0.00134	CcSEcCtD
Lisdexamfetamine—Urticaria—Acetazolamide—glaucoma	0.000218	0.00134	CcSEcCtD
Lisdexamfetamine—Tremor—Clonidine—glaucoma	0.000218	0.00134	CcSEcCtD
Lisdexamfetamine—Dyspepsia—Brinzolamide—glaucoma	0.000218	0.00134	CcSEcCtD
Lisdexamfetamine—Eye disorder—Betaxolol—glaucoma	0.000218	0.00133	CcSEcCtD
Lisdexamfetamine—Body temperature increased—Acetazolamide—glaucoma	0.000217	0.00133	CcSEcCtD
Lisdexamfetamine—Fatigue—Dorzolamide—glaucoma	0.000217	0.00133	CcSEcCtD
Lisdexamfetamine—Gastrointestinal disorder—Travoprost—glaucoma	0.000217	0.00133	CcSEcCtD
Lisdexamfetamine—Fatigue—Travoprost—glaucoma	0.000216	0.00132	CcSEcCtD
Lisdexamfetamine—Cardiac disorder—Betaxolol—glaucoma	0.000216	0.00132	CcSEcCtD
Lisdexamfetamine—SLC6A3—NRF2 pathway—SLC6A1—glaucoma	0.000216	0.00502	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Neuronal System—SLC6A1—glaucoma	0.000215	0.00501	CbGpPWpGaD
Lisdexamfetamine—Insomnia—Pilocarpine—glaucoma	0.000215	0.00132	CcSEcCtD
Lisdexamfetamine—Decreased appetite—Brinzolamide—glaucoma	0.000215	0.00132	CcSEcCtD
Lisdexamfetamine—Weight decreased—Timolol—glaucoma	0.000215	0.00132	CcSEcCtD
Lisdexamfetamine—Constipation—Travoprost—glaucoma	0.000214	0.00131	CcSEcCtD
Lisdexamfetamine—Agitation—Clonidine—glaucoma	0.000214	0.00131	CcSEcCtD
Lisdexamfetamine—Gastrointestinal disorder—Brinzolamide—glaucoma	0.000214	0.00131	CcSEcCtD
Lisdexamfetamine—Asthenia—Bimatoprost—glaucoma	0.000214	0.00131	CcSEcCtD
Lisdexamfetamine—Fatigue—Brinzolamide—glaucoma	0.000214	0.00131	CcSEcCtD
Lisdexamfetamine—Angioedema—Clonidine—glaucoma	0.000213	0.0013	CcSEcCtD
Lisdexamfetamine—Dyspnoea—Pilocarpine—glaucoma	0.000212	0.0013	CcSEcCtD
Lisdexamfetamine—Somnolence—Pilocarpine—glaucoma	0.000212	0.0013	CcSEcCtD
Lisdexamfetamine—Depression—Timolol—glaucoma	0.000211	0.00129	CcSEcCtD
Lisdexamfetamine—Immune system disorder—Betaxolol—glaucoma	0.00021	0.00129	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Apraclonidine—glaucoma	0.00021	0.00129	CcSEcCtD
Lisdexamfetamine—Mediastinal disorder—Betaxolol—glaucoma	0.00021	0.00129	CcSEcCtD
Lisdexamfetamine—Dyspepsia—Pilocarpine—glaucoma	0.00021	0.00128	CcSEcCtD
Lisdexamfetamine—SLC6A2—SLC-mediated transmembrane transport—SLC6A13—glaucoma	0.00021	0.00488	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—PEX19—glaucoma	0.000209	0.00487	CbGpPWpGaD
Lisdexamfetamine—Decreased appetite—Pilocarpine—glaucoma	0.000207	0.00127	CcSEcCtD
Lisdexamfetamine—Palpitations—Clonidine—glaucoma	0.000206	0.00126	CcSEcCtD
Lisdexamfetamine—Gastrointestinal disorder—Pilocarpine—glaucoma	0.000206	0.00126	CcSEcCtD
Lisdexamfetamine—Mental disorder—Betaxolol—glaucoma	0.000204	0.00125	CcSEcCtD
Lisdexamfetamine—Constipation—Pilocarpine—glaucoma	0.000204	0.00125	CcSEcCtD
Lisdexamfetamine—Dizziness—Apraclonidine—glaucoma	0.000203	0.00124	CcSEcCtD
Lisdexamfetamine—Malnutrition—Betaxolol—glaucoma	0.000203	0.00124	CcSEcCtD
Lisdexamfetamine—ADRA1B—GPCRs, Class A Rhodopsin-like—PTGFR—glaucoma	0.000201	0.00467	CbGpPWpGaD
Lisdexamfetamine—Urticaria—Dorzolamide—glaucoma	0.0002	0.00123	CcSEcCtD
Lisdexamfetamine—Body temperature increased—Dorzolamide—glaucoma	0.000199	0.00122	CcSEcCtD
Lisdexamfetamine—SLC6A2—NRF2 pathway—TGFB2—glaucoma	0.000198	0.00462	CbGpPWpGaD
Lisdexamfetamine—Anxiety—Clonidine—glaucoma	0.000198	0.00121	CcSEcCtD
Lisdexamfetamine—Asthenia—Acetazolamide—glaucoma	0.000197	0.00121	CcSEcCtD
Lisdexamfetamine—Dizziness—Bimatoprost—glaucoma	0.000197	0.00121	CcSEcCtD
Lisdexamfetamine—Nervousness—Betaxolol—glaucoma	0.000197	0.00121	CcSEcCtD
Lisdexamfetamine—Unspecified disorder of skin and subcutaneous tissue—Clonidine—glaucoma	0.000197	0.00121	CcSEcCtD
Lisdexamfetamine—Urticaria—Brinzolamide—glaucoma	0.000197	0.00121	CcSEcCtD
Lisdexamfetamine—Vomiting—Apraclonidine—glaucoma	0.000195	0.0012	CcSEcCtD
Lisdexamfetamine—Hypersensitivity—Brimonidine—glaucoma	0.000194	0.00119	CcSEcCtD
Lisdexamfetamine—Dry mouth—Clonidine—glaucoma	0.000194	0.00119	CcSEcCtD
Lisdexamfetamine—Dermatitis—Apraclonidine—glaucoma	0.000194	0.00119	CcSEcCtD
Lisdexamfetamine—Headache—Apraclonidine—glaucoma	0.000192	0.00118	CcSEcCtD
Lisdexamfetamine—Vision blurred—Betaxolol—glaucoma	0.000191	0.00117	CcSEcCtD
Lisdexamfetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—OPN4—glaucoma	0.000191	0.00445	CbGpPWpGaD
Lisdexamfetamine—Tremor—Betaxolol—glaucoma	0.00019	0.00116	CcSEcCtD
Lisdexamfetamine—Hallucination—Timolol—glaucoma	0.000189	0.00116	CcSEcCtD
Lisdexamfetamine—Asthenia—Brimonidine—glaucoma	0.000189	0.00116	CcSEcCtD
Lisdexamfetamine—Body temperature increased—Pilocarpine—glaucoma	0.000188	0.00115	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Acetazolamide—glaucoma	0.000188	0.00115	CcSEcCtD
Lisdexamfetamine—Rash—Bimatoprost—glaucoma	0.000188	0.00115	CcSEcCtD
Lisdexamfetamine—Dermatitis—Bimatoprost—glaucoma	0.000188	0.00115	CcSEcCtD
Lisdexamfetamine—Headache—Bimatoprost—glaucoma	0.000187	0.00114	CcSEcCtD
Lisdexamfetamine—Nervous system disorder—Clonidine—glaucoma	0.000186	0.00114	CcSEcCtD
Lisdexamfetamine—SLC6A3—SLC-mediated transmembrane transport—SLC6A13—glaucoma	0.000186	0.00432	CbGpPWpGaD
Lisdexamfetamine—Hypersensitivity—Dorzolamide—glaucoma	0.000186	0.00114	CcSEcCtD
Lisdexamfetamine—Tachycardia—Clonidine—glaucoma	0.000186	0.00114	CcSEcCtD
Lisdexamfetamine—Hypersensitivity—Travoprost—glaucoma	0.000185	0.00113	CcSEcCtD
Lisdexamfetamine—Skin disorder—Clonidine—glaucoma	0.000185	0.00113	CcSEcCtD
Lisdexamfetamine—Hyperhidrosis—Clonidine—glaucoma	0.000184	0.00113	CcSEcCtD
Lisdexamfetamine—Visual impairment—Timolol—glaucoma	0.000183	0.00112	CcSEcCtD
Lisdexamfetamine—Nausea—Apraclonidine—glaucoma	0.000182	0.00112	CcSEcCtD
Lisdexamfetamine—Hypersensitivity—Brinzolamide—glaucoma	0.000182	0.00112	CcSEcCtD
Lisdexamfetamine—Dizziness—Acetazolamide—glaucoma	0.000182	0.00111	CcSEcCtD
Lisdexamfetamine—Anorexia—Clonidine—glaucoma	0.000181	0.00111	CcSEcCtD
Lisdexamfetamine—Asthenia—Dorzolamide—glaucoma	0.000181	0.00111	CcSEcCtD
Lisdexamfetamine—Asthenia—Travoprost—glaucoma	0.00018	0.0011	CcSEcCtD
Lisdexamfetamine—Palpitations—Betaxolol—glaucoma	0.000179	0.0011	CcSEcCtD
Lisdexamfetamine—Eye disorder—Timolol—glaucoma	0.000178	0.00109	CcSEcCtD
Lisdexamfetamine—Asthenia—Brinzolamide—glaucoma	0.000178	0.00109	CcSEcCtD
Lisdexamfetamine—Nausea—Bimatoprost—glaucoma	0.000177	0.00108	CcSEcCtD
Lisdexamfetamine—Cardiac disorder—Timolol—glaucoma	0.000177	0.00108	CcSEcCtD
Lisdexamfetamine—SLC6A3—NRF2 pathway—TGFB2—glaucoma	0.000176	0.00409	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Neuronal System—SLC6A13—glaucoma	0.000175	0.00408	CbGpPWpGaD
Lisdexamfetamine—Hypersensitivity—Pilocarpine—glaucoma	0.000175	0.00107	CcSEcCtD
Lisdexamfetamine—Vomiting—Acetazolamide—glaucoma	0.000175	0.00107	CcSEcCtD
Lisdexamfetamine—Dizziness—Brimonidine—glaucoma	0.000174	0.00107	CcSEcCtD
Lisdexamfetamine—SLC6A2—Monoamine Transport—TNF—glaucoma	0.000173	0.00402	CbGpPWpGaD
Lisdexamfetamine—Diarrhoea—Dorzolamide—glaucoma	0.000172	0.00106	CcSEcCtD
Lisdexamfetamine—Headache—Acetazolamide—glaucoma	0.000172	0.00105	CcSEcCtD
Lisdexamfetamine—Anxiety—Betaxolol—glaucoma	0.000172	0.00105	CcSEcCtD
Lisdexamfetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—PTGFR—glaucoma	0.000172	0.004	CbGpPWpGaD
Lisdexamfetamine—Insomnia—Clonidine—glaucoma	0.000172	0.00105	CcSEcCtD
Lisdexamfetamine—Immune system disorder—Timolol—glaucoma	0.000172	0.00105	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Travoprost—glaucoma	0.000172	0.00105	CcSEcCtD
Lisdexamfetamine—Mediastinal disorder—Timolol—glaucoma	0.000172	0.00105	CcSEcCtD
Lisdexamfetamine—Unspecified disorder of skin and subcutaneous tissue—Betaxolol—glaucoma	0.000171	0.00105	CcSEcCtD
Lisdexamfetamine—Asthenia—Pilocarpine—glaucoma	0.000171	0.00105	CcSEcCtD
Lisdexamfetamine—Dyspnoea—Clonidine—glaucoma	0.000169	0.00104	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Brinzolamide—glaucoma	0.000169	0.00104	CcSEcCtD
Lisdexamfetamine—Somnolence—Clonidine—glaucoma	0.000169	0.00104	CcSEcCtD
Lisdexamfetamine—Dry mouth—Betaxolol—glaucoma	0.000169	0.00103	CcSEcCtD
Lisdexamfetamine—SLC6A3—Transmission across Chemical Synapses—SLC6A1—glaucoma	0.000168	0.0039	CbGpPWpGaD
Lisdexamfetamine—Mental disorder—Timolol—glaucoma	0.000167	0.00102	CcSEcCtD
Lisdexamfetamine—Dizziness—Dorzolamide—glaucoma	0.000167	0.00102	CcSEcCtD
Lisdexamfetamine—Rash—Brimonidine—glaucoma	0.000166	0.00102	CcSEcCtD
Lisdexamfetamine—Dermatitis—Brimonidine—glaucoma	0.000166	0.00102	CcSEcCtD
Lisdexamfetamine—Dizziness—Travoprost—glaucoma	0.000166	0.00102	CcSEcCtD
Lisdexamfetamine—Malnutrition—Timolol—glaucoma	0.000166	0.00101	CcSEcCtD
Lisdexamfetamine—Headache—Brimonidine—glaucoma	0.000165	0.00101	CcSEcCtD
Lisdexamfetamine—Decreased appetite—Clonidine—glaucoma	0.000165	0.00101	CcSEcCtD
Lisdexamfetamine—Gastrointestinal disorder—Clonidine—glaucoma	0.000164	0.00101	CcSEcCtD
Lisdexamfetamine—Fatigue—Clonidine—glaucoma	0.000164	0.001	CcSEcCtD
Lisdexamfetamine—Dizziness—Brinzolamide—glaucoma	0.000164	0.001	CcSEcCtD
Lisdexamfetamine—Nausea—Acetazolamide—glaucoma	0.000163	0.001	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Pilocarpine—glaucoma	0.000163	0.000998	CcSEcCtD
Lisdexamfetamine—Constipation—Clonidine—glaucoma	0.000163	0.000996	CcSEcCtD
Lisdexamfetamine—Nervous system disorder—Betaxolol—glaucoma	0.000162	0.000994	CcSEcCtD
Lisdexamfetamine—Tachycardia—Betaxolol—glaucoma	0.000162	0.000989	CcSEcCtD
Lisdexamfetamine—Nervousness—Timolol—glaucoma	0.000161	0.000986	CcSEcCtD
Lisdexamfetamine—Skin disorder—Betaxolol—glaucoma	0.000161	0.000985	CcSEcCtD
Lisdexamfetamine—Vomiting—Dorzolamide—glaucoma	0.00016	0.000981	CcSEcCtD
Lisdexamfetamine—Hyperhidrosis—Betaxolol—glaucoma	0.00016	0.00098	CcSEcCtD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—SLC4A4—glaucoma	0.00016	0.00371	CbGpPWpGaD
Lisdexamfetamine—Rash—Dorzolamide—glaucoma	0.000159	0.000973	CcSEcCtD
Lisdexamfetamine—Dermatitis—Dorzolamide—glaucoma	0.000159	0.000972	CcSEcCtD
Lisdexamfetamine—SLC18A2—Transmembrane transport of small molecules—SLC6A13—glaucoma	0.000158	0.00368	CbGpPWpGaD
Lisdexamfetamine—Rash—Travoprost—glaucoma	0.000158	0.000969	CcSEcCtD
Lisdexamfetamine—Dermatitis—Travoprost—glaucoma	0.000158	0.000968	CcSEcCtD
Lisdexamfetamine—Headache—Dorzolamide—glaucoma	0.000158	0.000967	CcSEcCtD
Lisdexamfetamine—Anorexia—Betaxolol—glaucoma	0.000158	0.000966	CcSEcCtD
Lisdexamfetamine—Vomiting—Brinzolamide—glaucoma	0.000157	0.000965	CcSEcCtD
Lisdexamfetamine—Dizziness—Pilocarpine—glaucoma	0.000157	0.000964	CcSEcCtD
Lisdexamfetamine—Headache—Travoprost—glaucoma	0.000157	0.000963	CcSEcCtD
Lisdexamfetamine—Nausea—Brimonidine—glaucoma	0.000157	0.00096	CcSEcCtD
Lisdexamfetamine—Rash—Brinzolamide—glaucoma	0.000156	0.000957	CcSEcCtD
Lisdexamfetamine—Vision blurred—Timolol—glaucoma	0.000156	0.000956	CcSEcCtD
Lisdexamfetamine—Dermatitis—Brinzolamide—glaucoma	0.000156	0.000956	CcSEcCtD
Lisdexamfetamine—Headache—Brinzolamide—glaucoma	0.000155	0.00095	CcSEcCtD
Lisdexamfetamine—SLC6A2—SLC-mediated transmembrane transport—SLC6A1—glaucoma	0.000153	0.00357	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Monoamine Transport—TNF—glaucoma	0.000153	0.00356	CbGpPWpGaD
Lisdexamfetamine—Angioedema—Timolol—glaucoma	0.000151	0.000927	CcSEcCtD
Lisdexamfetamine—Vomiting—Pilocarpine—glaucoma	0.000151	0.000927	CcSEcCtD
Lisdexamfetamine—Urticaria—Clonidine—glaucoma	0.000151	0.000925	CcSEcCtD
Lisdexamfetamine—Body temperature increased—Clonidine—glaucoma	0.00015	0.00092	CcSEcCtD
Lisdexamfetamine—Rash—Pilocarpine—glaucoma	0.00015	0.000919	CcSEcCtD
Lisdexamfetamine—Dermatitis—Pilocarpine—glaucoma	0.00015	0.000919	CcSEcCtD
Lisdexamfetamine—Insomnia—Betaxolol—glaucoma	0.00015	0.000917	CcSEcCtD
Lisdexamfetamine—Nausea—Dorzolamide—glaucoma	0.00015	0.000917	CcSEcCtD
Lisdexamfetamine—Headache—Pilocarpine—glaucoma	0.000149	0.000913	CcSEcCtD
Lisdexamfetamine—Nausea—Travoprost—glaucoma	0.000149	0.000913	CcSEcCtD
Lisdexamfetamine—Dyspnoea—Betaxolol—glaucoma	0.000148	0.000904	CcSEcCtD
Lisdexamfetamine—Nausea—Brinzolamide—glaucoma	0.000147	0.000901	CcSEcCtD
Lisdexamfetamine—Palpitations—Timolol—glaucoma	0.000146	0.000897	CcSEcCtD
Lisdexamfetamine—Dyspepsia—Betaxolol—glaucoma	0.000146	0.000892	CcSEcCtD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—OPN4—glaucoma	0.000145	0.00339	CbGpPWpGaD
Lisdexamfetamine—Decreased appetite—Betaxolol—glaucoma	0.000144	0.000881	CcSEcCtD
Lisdexamfetamine—Hypertension—Timolol—glaucoma	0.000143	0.000876	CcSEcCtD
Lisdexamfetamine—Gastrointestinal disorder—Betaxolol—glaucoma	0.000143	0.000875	CcSEcCtD
Lisdexamfetamine—Fatigue—Betaxolol—glaucoma	0.000143	0.000874	CcSEcCtD
Lisdexamfetamine—Constipation—Betaxolol—glaucoma	0.000142	0.000867	CcSEcCtD
Lisdexamfetamine—Nausea—Pilocarpine—glaucoma	0.000141	0.000866	CcSEcCtD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—SLC4A4—glaucoma	0.000141	0.00329	CbGpPWpGaD
Lisdexamfetamine—Anxiety—Timolol—glaucoma	0.000141	0.000861	CcSEcCtD
Lisdexamfetamine—Unspecified disorder of skin and subcutaneous tissue—Timolol—glaucoma	0.00014	0.000858	CcSEcCtD
Lisdexamfetamine—Hypersensitivity—Clonidine—glaucoma	0.00014	0.000858	CcSEcCtD
Lisdexamfetamine—Dry mouth—Timolol—glaucoma	0.000138	0.000845	CcSEcCtD
Lisdexamfetamine—Asthenia—Clonidine—glaucoma	0.000136	0.000835	CcSEcCtD
Lisdexamfetamine—SLC6A3—SLC-mediated transmembrane transport—SLC6A1—glaucoma	0.000136	0.00316	CbGpPWpGaD
Lisdexamfetamine—Anaphylactic shock—Timolol—glaucoma	0.000135	0.000828	CcSEcCtD
Lisdexamfetamine—SLC6A2—NRF2 pathway—GSTM1—glaucoma	0.000135	0.00314	CbGpPWpGaD
Lisdexamfetamine—Nervous system disorder—Timolol—glaucoma	0.000133	0.000812	CcSEcCtD
Lisdexamfetamine—ADRA1B—LPA receptor mediated events—MMP2—glaucoma	0.000132	0.00308	CbGpPWpGaD
Lisdexamfetamine—Urticaria—Betaxolol—glaucoma	0.000131	0.000805	CcSEcCtD
Lisdexamfetamine—Skin disorder—Timolol—glaucoma	0.000131	0.000804	CcSEcCtD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—PTGFR—glaucoma	0.000131	0.00305	CbGpPWpGaD
Lisdexamfetamine—Body temperature increased—Betaxolol—glaucoma	0.000131	0.000801	CcSEcCtD
Lisdexamfetamine—Hyperhidrosis—Timolol—glaucoma	0.000131	0.000801	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Clonidine—glaucoma	0.00013	0.000797	CcSEcCtD
Lisdexamfetamine—Anorexia—Timolol—glaucoma	0.000129	0.000789	CcSEcCtD
Lisdexamfetamine—SLC6A3—Neuronal System—SLC6A1—glaucoma	0.000128	0.00299	CbGpPWpGaD
Lisdexamfetamine—Dizziness—Clonidine—glaucoma	0.000126	0.00077	CcSEcCtD
Lisdexamfetamine—Insomnia—Timolol—glaucoma	0.000122	0.000749	CcSEcCtD
Lisdexamfetamine—Hypersensitivity—Betaxolol—glaucoma	0.000122	0.000747	CcSEcCtD
Lisdexamfetamine—Vomiting—Clonidine—glaucoma	0.000121	0.00074	CcSEcCtD
Lisdexamfetamine—Dyspnoea—Timolol—glaucoma	0.000121	0.000738	CcSEcCtD
Lisdexamfetamine—Somnolence—Timolol—glaucoma	0.00012	0.000736	CcSEcCtD
Lisdexamfetamine—Rash—Clonidine—glaucoma	0.00012	0.000734	CcSEcCtD
Lisdexamfetamine—Dermatitis—Clonidine—glaucoma	0.00012	0.000734	CcSEcCtD
Lisdexamfetamine—SLC6A3—NRF2 pathway—GSTM1—glaucoma	0.000119	0.00278	CbGpPWpGaD
Lisdexamfetamine—Headache—Clonidine—glaucoma	0.000119	0.000729	CcSEcCtD
Lisdexamfetamine—Dyspepsia—Timolol—glaucoma	0.000119	0.000729	CcSEcCtD
Lisdexamfetamine—Asthenia—Betaxolol—glaucoma	0.000119	0.000727	CcSEcCtD
Lisdexamfetamine—Decreased appetite—Timolol—glaucoma	0.000118	0.00072	CcSEcCtD
Lisdexamfetamine—Gastrointestinal disorder—Timolol—glaucoma	0.000117	0.000715	CcSEcCtD
Lisdexamfetamine—Fatigue—Timolol—glaucoma	0.000117	0.000714	CcSEcCtD
Lisdexamfetamine—SLC18A2—Transmembrane transport of small molecules—SLC6A1—glaucoma	0.000116	0.0027	CbGpPWpGaD
Lisdexamfetamine—Diarrhoea—Betaxolol—glaucoma	0.000113	0.000694	CcSEcCtD
Lisdexamfetamine—Nausea—Clonidine—glaucoma	0.000113	0.000692	CcSEcCtD
Lisdexamfetamine—Dizziness—Betaxolol—glaucoma	0.000109	0.00067	CcSEcCtD
Lisdexamfetamine—Urticaria—Timolol—glaucoma	0.000107	0.000658	CcSEcCtD
Lisdexamfetamine—Body temperature increased—Timolol—glaucoma	0.000107	0.000655	CcSEcCtD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—SLC6A13—glaucoma	0.000106	0.00248	CbGpPWpGaD
Lisdexamfetamine—Vomiting—Betaxolol—glaucoma	0.000105	0.000645	CcSEcCtD
Lisdexamfetamine—Rash—Betaxolol—glaucoma	0.000104	0.000639	CcSEcCtD
Lisdexamfetamine—Dermatitis—Betaxolol—glaucoma	0.000104	0.000639	CcSEcCtD
Lisdexamfetamine—Headache—Betaxolol—glaucoma	0.000104	0.000635	CcSEcCtD
Lisdexamfetamine—Hypersensitivity—Timolol—glaucoma	9.96e-05	0.00061	CcSEcCtD
Lisdexamfetamine—ADRA1B—LPA receptor mediated events—MMP9—glaucoma	9.95e-05	0.00232	CbGpPWpGaD
Lisdexamfetamine—Nausea—Betaxolol—glaucoma	9.83e-05	0.000602	CcSEcCtD
Lisdexamfetamine—Asthenia—Timolol—glaucoma	9.7e-05	0.000594	CcSEcCtD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—SLC6A13—glaucoma	9.43e-05	0.0022	CbGpPWpGaD
Lisdexamfetamine—Diarrhoea—Timolol—glaucoma	9.25e-05	0.000567	CcSEcCtD
Lisdexamfetamine—Dizziness—Timolol—glaucoma	8.94e-05	0.000548	CcSEcCtD
Lisdexamfetamine—ADRA1B—G alpha (q) signalling events—EDN1—glaucoma	8.63e-05	0.00201	CbGpPWpGaD
Lisdexamfetamine—Vomiting—Timolol—glaucoma	8.6e-05	0.000527	CcSEcCtD
Lisdexamfetamine—Rash—Timolol—glaucoma	8.52e-05	0.000522	CcSEcCtD
Lisdexamfetamine—Dermatitis—Timolol—glaucoma	8.52e-05	0.000522	CcSEcCtD
Lisdexamfetamine—Headache—Timolol—glaucoma	8.47e-05	0.000519	CcSEcCtD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—OPN4—glaucoma	8.22e-05	0.00191	CbGpPWpGaD
Lisdexamfetamine—Nausea—Timolol—glaucoma	8.03e-05	0.000492	CcSEcCtD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—SLC6A1—glaucoma	7.79e-05	0.00181	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—EDN1—glaucoma	7.72e-05	0.0018	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—OPN4—glaucoma	7.47e-05	0.00174	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—PTGFR—glaucoma	7.4e-05	0.00172	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—SLC6A1—glaucoma	6.9e-05	0.00161	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—PTGFR—glaucoma	6.72e-05	0.00156	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—SMO—glaucoma	6.6e-05	0.00154	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—LRP12—glaucoma	6.36e-05	0.00148	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—AMPK Signaling—TP53—glaucoma	6.36e-05	0.00148	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—EDN1—glaucoma	5.72e-05	0.00133	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—C3—glaucoma	5e-05	0.00116	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—OPN4—glaucoma	4.41e-05	0.00103	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—EDN1—glaucoma	4.35e-05	0.00101	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—HEYL—glaucoma	4.1e-05	0.000954	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PTGFR—glaucoma	3.97e-05	0.000924	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—C3—glaucoma	3.8e-05	0.000886	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—SMO—glaucoma	3.39e-05	0.000789	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—RPTOR—glaucoma	3.11e-05	0.000723	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—NCK2—glaucoma	3.01e-05	0.000701	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—HDAC9—glaucoma	2.56e-05	0.000596	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—EDN1—glaucoma	2.46e-05	0.000573	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—EDN1—glaucoma	2.23e-05	0.00052	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—C3—glaucoma	2.15e-05	0.0005	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—SMO—glaucoma	2e-05	0.000466	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—C3—glaucoma	1.95e-05	0.000454	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—NTRK2—glaucoma	1.83e-05	0.000426	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—NGFR—glaucoma	1.57e-05	0.000366	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—NTRK1—glaucoma	1.49e-05	0.000348	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CDKN2B—glaucoma	1.38e-05	0.00032	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—EDN1—glaucoma	1.32e-05	0.000307	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—NGF—glaucoma	1.21e-05	0.000282	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—C3—glaucoma	1.15e-05	0.000268	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—APOE—glaucoma	1.07e-05	0.00025	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CAV1—glaucoma	1.06e-05	0.000248	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—FN1—glaucoma	1.01e-05	0.000236	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—BAD—glaucoma	1e-05	0.000233	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—NOS3—glaucoma	8.04e-06	0.000187	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CDKN1B—glaucoma	6.97e-06	0.000162	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—MMP9—glaucoma	6.45e-06	0.00015	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—VEGFA—glaucoma	5.79e-06	0.000135	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—TP53—glaucoma	4.38e-06	0.000102	CbGpPWpGaD
